How to Prevent Heart Failure Readmission by Using Lung Impedance Device (HOPE-HF Study) - Trial NCT04080388
Access comprehensive clinical trial information for NCT04080388 through Pure Global AI's free database. This Phase 3 trial is sponsored by Hillel Yaffe Medical Center and is currently status unknown. The study focuses on Heart Failure Acute. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hillel Yaffe Medical Center
Timeline & Enrollment
Phase 3
Sep 01, 2019
Sep 01, 2021
Primary Outcome
Prevention of heart failure re-admission,Prevention of heart failure re-admission
Summary
The readmission of Heart Failure (HF) patients for exacerbation HF within 30-day is unmet
 goal. The mail reason for readmission is excessive accumulation of fluid in patient's lung.
 According our data (1,2) around 40% of HF patient have excessive lung fluid at discharge from
 HF hospitalization (unacceptable residual congestion on discharge). In other words, around
 40% patients are discharged from HF hospitalization prematurely when they are not ready to be
 discharged. Only 60% of HF patients are discharged from HF admission with acceptable level
 of residual pulmonary congestion (2). There are some techniques to assess readiness of HF
 patients for discharge. Pulmonary congestion (lung fluid accumulation) may be assessed
 non-invasively by measurement Brain Natriuretic Peptide (BNP), (3,4), by lung ultrasound
 (LUS), (5-7) and by Lung Impedance (LI) method (1,2). LUS is operator depended technique. LI
 and BNP techniques are most reliable methods (2) and easy to use.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04080388
Non-Device Trial